PRCD

Summary

PRCD (photoreceptor disc component, HGNC:32528) is a protein-coding gene on chromosome 17q25.1, encoding Photoreceptor disk component PRCD (Q00LT1). Involved in vision.

This gene is predominantly expressed in the retina, and mutations in this gene are the cause of autosomal recessive retinal degeneration in both humans and dogs. Alternatively spliced transcript variants have been found for this gene.

Source: NCBI Gene 768206 — RefSeq curated summary.

At a glance

• Gene–disease (curated): retinitis pigmentosa 36 (Definitive, GenCC) — +1 more curated relationship
• GWAS associations: 2
• Clinical variants (ClinVar): 33 total — 3 pathogenic
• Phenotypes (HPO): 35
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity no evidence
• MANE Select transcript: NM_001077620

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32528
Approved symbol	PRCD
Name	photoreceptor disc component
Location	17q25.1
Locus type	gene with protein product
Status	Approved
Aliases	RP36
Ensembl gene	ENSG00000214140
Ensembl biotype	protein_coding
OMIM	610598
Entrez	768206

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 10 protein_coding_CDS_not_defined, 2 protein_coding, 1 retained_intron

ENST00000397630, ENST00000397633, ENST00000465808, ENST00000586148, ENST00000587063, ENST00000587289, ENST00000587813, ENST00000590555, ENST00000591317, ENST00000592014, ENST00000592340, ENST00000592432, ENST00000593023

RefSeq mRNA: 1 — MANE Select: NM_001077620 NM_001077620

CCDS: CCDS42382

Canonical transcript exons

ENST00000592014 — 5 exons

Exon	Start	End
ENSE00001529466	76543803	76545376
ENSE00001649319	76540044	76540215
ENSE00002838652	76543029	76543121
ENSE00003560166	76542553	76542633
ENSE00003582824	76540505	76540573

Expression profiles

Bgee: expression breadth ubiquitous, 196 present calls, max score 95.15.

FANTOM5 (CAGE): breadth broad, TPM avg 5.0495 / max 5210.3187, expressed in 271 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
162865	1.8964	109
162866	1.8766	112
162864	0.6390	92
162856	0.3894	14
162855	0.0740	23
162862	0.0555	27
162859	0.0400	6
162863	0.0284	14
162857	0.0232	6
162858	0.0171	6

Top tissues by expression

250 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	95.15	gold quality
cerebellar hemisphere	UBERON:0002245	94.74	gold quality
cerebellar cortex	UBERON:0002129	94.51	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	94.35	gold quality
cerebellum	UBERON:0002037	92.98	gold quality
spinal cord	UBERON:0002240	92.26	gold quality
substantia nigra	UBERON:0002038	86.93	gold quality
Brodmann (1909) area 9	UBERON:0013540	86.22	gold quality
midbrain	UBERON:0001891	85.25	gold quality
hypothalamus	UBERON:0001898	85.02	gold quality
right atrium auricular region	UBERON:0006631	84.15	gold quality
cardiac muscle of right atrium	UBERON:0003379	84.12	silver quality
endocervix	UBERON:0000458	84.07	gold quality
right frontal lobe	UBERON:0002810	83.88	gold quality
cardiac atrium	UBERON:0002081	83.70	gold quality
corpus callosum	UBERON:0002336	83.28	gold quality
spleen	UBERON:0002106	82.67	gold quality
apex of heart	UBERON:0002098	82.23	gold quality
inferior vagus X ganglion	UBERON:0005363	82.07	gold quality
putamen	UBERON:0001874	82.06	gold quality
prefrontal cortex	UBERON:0000451	82.05	gold quality
Ammon’s horn	UBERON:0001954	81.96	gold quality
subcutaneous adipose tissue	UBERON:0002190	81.86	gold quality
amygdala	UBERON:0001876	81.75	gold quality
omental fat pad	UBERON:0010414	81.70	gold quality
peritoneum	UBERON:0002358	81.63	gold quality
left ventricle myocardium	UBERON:0006566	81.37	gold quality
anterior cingulate cortex	UBERON:0009835	81.36	gold quality
ectocervix	UBERON:0012249	81.29	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	81.22	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-7316	yes	61.35
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

57 targeting PRCD, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-646	99.68	67.84	1645
HSA-MIR-3679-3P	99.64	69.88	1599
HSA-MIR-1260A	99.61	66.67	1098
HSA-MIR-1260B	99.61	66.67	1098
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-6733-3P	99.54	67.80	1281
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-4291	99.20	68.88	2969
HSA-MIR-6734-3P	99.15	66.27	1627
HSA-MIR-4478	99.07	65.16	2320
HSA-MIR-5001-5P	99.05	66.76	1972
HSA-MIR-3619-5P	99.00	68.87	2308
HSA-MIR-6876-3P	98.97	65.69	765
HSA-MIR-939-3P	98.97	65.07	2347
HSA-MIR-4711-5P	98.89	68.00	965

Functional genomics

ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 3)

• The identification of a second pathogenic mutation of PRCD in multiple retinitis pigmentosa (RP) patients confirms the role of PRCD in the aetiology of RP in humans. (PMID:20507925)
• The identification of a third mutation in PRCD confirms its role in the pathogenesis of retinitis pigmentosa. (PMID:23805042)
• Disrupting PRCD palmitoylation eliminating the modified cysteine dramatically affects the stability of PRCD. (PMID:27613864)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Prcd	ENSMUSG00000075410
rattus_norvegicus	Prcd	ENSRNOG00000090755

Protein

Protein identifiers

Photoreceptor disk component PRCD — Q00LT1 (reviewed: Q00LT1)

Alternative names: Progressive rod-cone degeneration protein

All UniProt accessions (1): Q00LT1

UniProt curated annotations — full annotation on UniProt →

Function. Involved in vision.

Subunit / interactions. Interacts with RHO/rhodopsin; the interaction promotes PRCD stability.

Subcellular location. Cell projection. Cilium. Photoreceptor outer segment. Membrane. Endoplasmic reticulum. Golgi apparatus.

Post-translational modifications. Palmitoylated at Cys-2. Palmitoylation is essential for protein stability and trafficking to the photoreceptor outer segment, but does not appear to be essential for membrane localization. Probably palmitoylated by ZDHHC3. Phosphorylated.

Disease relevance. Retinitis pigmentosa 36 (RP36) [MIM:610599] A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the PRCD family.

RefSeq proteins (1): NP_001071088* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR027937	PRCD	Family

Pfam: PF15201

UniProt features (7 total): sequence variant 4, chain 1, region of interest 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q00LT1-F1	65.20	0.09

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 115 (showing top): GOBP_SENSORY_PERCEPTION_OF_LIGHT_STIMULUS, GOBP_RESPONSE_TO_RADIATION, GOBP_DETECTION_OF_LIGHT_STIMULUS, GOBP_RESPONSE_TO_ABIOTIC_STIMULUS, GOBP_DETECTION_OF_ABIOTIC_STIMULUS, GOBP_DETECTION_OF_STIMULUS, GOBP_SENSORY_PERCEPTION, GOBP_DETECTION_OF_LIGHT_STIMULUS_INVOLVED_IN_SENSORY_PERCEPTION, GOCC_NEURON_PROJECTION, GOBP_RESPONSE_TO_LIGHT_STIMULUS, GOCC_CELL_PROJECTION_MEMBRANE, GOCC_PHOTORECEPTOR_OUTER_SEGMENT_MEMBRANE, GOCC_PLASMA_MEMBRANE_REGION, GOCC_CILIARY_MEMBRANE, GOCC_CILIUM

GO Biological Process (2): detection of light stimulus involved in visual perception (GO:0050908), visual perception (GO:0007601)

GO Molecular Function (1): opsin binding (GO:0002046)

GO Cellular Component (8): extracellular region (GO:0005576), cytoplasm (GO:0005737), endoplasmic reticulum (GO:0005783), Golgi apparatus (GO:0005794), photoreceptor outer segment membrane (GO:0042622), photoreceptor outer segment (GO:0001750), membrane (GO:0016020), cell projection (GO:0042995)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
cytoplasm	2
endomembrane system	2
intracellular membrane-bounded organelle	2
visual perception	1
detection of light stimulus involved in sensory perception	1
sensory perception of light stimulus	1
protein binding	1
intracellular anatomical structure	1
photoreceptor outer segment	1
ciliary membrane	1
photoreceptor cell cilium	1

Protein interactions and networks

STRING

422 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PRCD	GUCA1B	Q9UMX6	884
PRCD	PCARE	A6NGG8	832
PRCD	IMPG2	Q9BZV3	819
PRCD	PDE6A	P16499	816
PRCD	CNGB1	Q14028	811
PRCD	ZNF513	Q8N8E2	806
PRCD	CERKL	Q49MI3	800
PRCD	EYS	Q5T1H1	800
PRCD	IDH3B	O43837	781
PRCD	PDE6G	P18545	779
PRCD	TULP1	O00294	777
PRCD	CNGA1	P29973	774
PRCD	RPE65	Q16518	754
PRCD	RHO	P08100	754
PRCD	PDE6B	P35913	751

IntAct

0 interactions, top by confidence:

BioGRID (3): PRCD (Affinity Capture-MS), PRCD (Cross-Linking-MS (XL-MS)), PRCD (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A023IWE0, A0A023IWE1, A0A023IWG1, A0A023IWG2, A0A023IWI8, A0A023IWK3, A0A023IWK5, A0A023IWM4, A0QRX8, A2BT05, A2BYF5, A2C4H7, A2SSV2, A8W7M6, A8W7N1, A8W7N4, A8W7N6, A8W7N7, A8W7P3, A9ILJ1, B0R4Y7, P08229, P0CU65, P0DKH4, P10217, P11925, P22660, P24111, P55358, P55536, P55671, P81080, P84546, P9WL08, P9WL09, Q00LT1, Q00LT2, Q00LT9, Q03284, Q09T02

Diamond homologs: E1B7R9, Q00LT1, Q00LT2, Q00LT9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

33 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	0
Uncertain significance	23
Likely benign	0
Benign	3

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
3243136	NC_000017.10:g.(?74536224)(74538656_?)del	Pathogenic
37041	NM_001077620.3(PRCD):c.64C>T (p.Arg22Ter)	Pathogenic
987020	NM_001077620.3(PRCD):c.52C>T (p.Arg18Ter)	Pathogenic

SpliceAI

1277 predictions. Top by Δscore:

Variant	Effect	Δscore
17:76530972:T:TA	donor_gain	1.0000
17:76530977:A:AC	donor_gain	1.0000
17:76530978:C:CC	donor_gain	1.0000
17:76531015:T:TA	donor_gain	1.0000
17:76531016:C:A	donor_gain	1.0000
17:76531142:TC:T	acceptor_loss	1.0000
17:76531143:C:CA	acceptor_loss	1.0000
17:76531143:C:CC	acceptor_gain	1.0000
17:76531144:T:G	acceptor_loss	1.0000
17:76531687:AGAAC:A	acceptor_gain	1.0000
17:76531688:GAAC:G	acceptor_gain	1.0000
17:76531690:AC:A	acceptor_gain	1.0000
17:76531691:CC:C	acceptor_gain	1.0000
17:76531692:C:CA	acceptor_loss	1.0000
17:76531692:C:CC	acceptor_gain	1.0000
17:76531693:T:A	acceptor_loss	1.0000
17:76531696:C:CT	acceptor_gain	1.0000
17:76540216:G:GG	donor_gain	1.0000
17:76530974:CTCAC:C	donor_loss	0.9900
17:76530975:TCACG:T	donor_loss	0.9900
17:76530976:CACG:C	donor_loss	0.9900
17:76530977:A:G	donor_loss	0.9900
17:76530978:C:G	donor_loss	0.9900
17:76531012:ACTT:A	donor_gain	0.9900
17:76531013:CTTC:C	donor_gain	0.9900
17:76531138:AGGAT:A	acceptor_gain	0.9900
17:76531139:GGAT:G	acceptor_gain	0.9900
17:76531150:C:CT	acceptor_gain	0.9900
17:76531477:C:CT	donor_gain	0.9900
17:76531478:C:CT	donor_gain	0.9900

AlphaMissense

345 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:76540166:A:C	S9R	0.988
17:76540168:C:A	S9R	0.988
17:76540168:C:G	S9R	0.988
17:76540145:T:C	C2R	0.965
17:76540176:C:A	A12D	0.961
17:76540161:T:G	L7R	0.947
17:76540164:T:A	L8H	0.946
17:76540161:T:A	L7Q	0.934
17:76540164:T:G	L8R	0.930
17:76540152:C:A	T4N	0.911
17:76540147:C:G	C2W	0.907
17:76540187:C:A	R16S	0.898
17:76540152:C:T	T4I	0.896
17:76540173:T:G	L11R	0.893
17:76540146:G:A	C2Y	0.883
17:76540149:C:A	T3N	0.880
17:76540149:C:T	T3I	0.876
17:76540158:T:C	F6S	0.875
17:76540161:T:C	L7P	0.872
17:76540155:T:A	L5H	0.867
17:76540173:T:A	L11Q	0.856
17:76540188:G:C	R16P	0.840
17:76540155:T:G	L5R	0.838
17:76540167:G:A	S9N	0.837
17:76540196:T:C	F19L	0.834
17:76540198:T:A	F19L	0.834
17:76540198:T:G	F19L	0.834
17:76540173:T:C	L11P	0.822
17:76540164:T:C	L8P	0.814
17:76540184:T:A	W15R	0.814

dbSNP variants (sampled 300 via entrez): RS1000024337 (17:76528830 G>C,T), RS1000033374 (17:76530597 GGGA>G), RS1000106451 (17:76530842 A>G), RS1000308964 (17:76527670 G>A,C), RS1000313371 (17:76536586 G>C,T), RS1000344192 (17:76541620 G>T), RS1000483914 (17:76542941 G>A,T), RS1000577548 (17:76547315 G>C), RS1000685078 (17:76536252 A>C), RS1000688015 (17:76552030 T>G), RS1000711510 (17:76548661 T>C), RS1000779083 (17:76550153 A>C,G), RS1000905016 (17:76546982 G>A), RS1000985664 (17:76536277 C>A,G,T), RS1001058093 (17:76526476 C>T)

Disease associations

OMIM: gene MIM:610598 | disease phenotypes: MIM:268000, MIM:610599

GenCC curated gene-disease

Disease	Classification	Inheritance
retinitis pigmentosa 36	Definitive	Autosomal recessive
retinitis pigmentosa	Supportive	Autosomal dominant

Mondo (3): inherited retinal dystrophy (MONDO:0019118), retinitis pigmentosa (MONDO:0019200), retinitis pigmentosa 36 (MONDO:0012523)

Orphanet (2): OBSOLETE: Inherited retinal disorder (Orphanet:71862), Retinitis pigmentosa (Orphanet:791)

HPO phenotypes

35 total (30 of 35 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000405	Conductive hearing impairment
HP:0000407	Sensorineural hearing impairment
HP:0000501	Glaucoma
HP:0000505	Visual impairment
HP:0000510	Rod-cone dystrophy
HP:0000512	Abnormal electroretinogram
HP:0000543	Optic disc pallor
HP:0000546	Retinal degeneration
HP:0000550	Undetectable electroretinogram
HP:0000551	Color vision defect
HP:0000563	Keratoconus
HP:0000602	Ophthalmoplegia
HP:0000608	Macular degeneration
HP:0000613	Photophobia
HP:0000618	Blindness
HP:0000639	Nystagmus
HP:0000648	Optic atrophy
HP:0000662	Nyctalopia
HP:0000842	Hyperinsulinemia
HP:0001105	Retinal atrophy
HP:0007663	Reduced visual acuity
HP:0007675	Progressive night blindness
HP:0007703	Abnormal retinal pigmentation
HP:0007737	Spicular pigmentation of the retina
HP:0007787	Posterior subcapsular cataract
HP:0007843	Attenuation of retinal blood vessels
HP:0007994	Peripheral visual field loss
HP:0008046	Abnormal retinal vascular morphology
HP:0011505	Cystoid macular edema

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST007021_2	Type 2 diabetes nephropathy	1.000000e-06
GCST007022_4	Type 2 diabetes nephropathy including microalbuminuria	1.000000e-06

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D058499	Retinal Dystrophies	C11.768.585.658
D012174	Retinitis Pigmentosa	C11.270.684; C11.768.585.658.500; C16.320.290.684
C566431	Retinitis Pigmentosa 36 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Particulate Matter	increases abundance, increases expression, decreases expression	2
ferrous chloride	decreases expression	1
nutlin 3	increases expression	1
jinfukang	affects cotreatment, increases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Benzo(a)pyrene	decreases methylation	1
Cisplatin	affects cotreatment, increases expression	1
Dactinomycin	increases expression	1
Nickel	decreases expression	1
Phthalic Acids	increases methylation	1
Smoke	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Triclosan	increases expression	1
Valproic Acid	increases methylation	1
Antirheumatic Agents	decreases expression	1

Clinical trials (associated diseases)

259 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT00000114	PHASE3	COMPLETED	Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
NCT00000116	PHASE3	COMPLETED	Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
NCT00346333	PHASE3	COMPLETED	Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
NCT01786395	PHASE3	TERMINATED	Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
NCT04224207	PHASE3	COMPLETED	Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton’s Jelly Derived Mesenchymal Stem Cells
NCT04636853	PHASE3	COMPLETED	CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
NCT05537220	PHASE3	ACTIVE_NOT_RECRUITING	Oral N-acetylcysteine for Retinitis Pigmentosa
NCT05800301	PHASE3	COMPLETED	Management of Retinitis Pigmentosa Via Combination of Wharton’s Jelly-derived Mesenchymal Stem Cells and Magnovision
NCT05926583	PHASE3	ACTIVE_NOT_RECRUITING	A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
NCT06388200	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT07082855	PHASE3	NOT_YET_RECRUITING	A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
NCT07290530	PHASE3	NOT_YET_RECRUITING	24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
NCT00100230	PHASE2	COMPLETED	DHA and X-Linked Retinitis Pigmentosa
NCT00447980	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447993	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
NCT01233609	PHASE2	COMPLETED	Trial of Oral Valproic Acid for Retinitis Pigmentosa
NCT01399515	PHASE2	COMPLETED	Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
NCT01530659	PHASE2	COMPLETED	Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
NCT01560715	PHASE2	COMPLETED	Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
NCT02609165	PHASE2	COMPLETED	Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
NCT02661711	PHASE2	COMPLETED	Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study
NCT02804360	PHASE2	UNKNOWN	Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study
NCT02837640	PHASE2	UNKNOWN	Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa
NCT03073733	PHASE2	COMPLETED	Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
NCT04068207	PHASE2	COMPLETED	Minocycline Treatment in Retinitis Pigmentosa
NCT04356716	PHASE2	COMPLETED	Sildenafil for Treatment of Choroidal Ischemia
NCT04604899	PHASE2	COMPLETED	Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
NCT04763369	PHASE2	UNKNOWN	Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)
NCT04864496	PHASE2	UNKNOWN	Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa
NCT04945772	PHASE2	COMPLETED	Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
NCT05085964	PHASE2	TERMINATED	An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
NCT05392179	PHASE2	COMPLETED	A Study in Subjects With Retinitis Pigmentosa
NCT06627179	PHASE2	RECRUITING	Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06628947	PHASE2	RECRUITING	A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
NCT06912633	PHASE2	RECRUITING	Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
NCT03763227	PHASE2	COMPLETED	Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy
NCT00063765	PHASE1	COMPLETED	Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye
NCT00065455	PHASE1	COMPLETED	Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
NCT00458575	PHASE1	TERMINATED	A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa